Security Snapshot

TScan Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share (TCRX) Institutional Ownership

CUSIP: 89854M101

13F Institutional Holders and Ownership History from Q3 2021 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

59

Shares (Excl. Options)

30,693,293

Price

$1.00

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.

Create free account to save this page Review latest holder period
Type / Class
Equity / Voting Common Stock, par value $0.0001 per share
Symbol
TCRX on Nasdaq
Shares outstanding
52,382,313
Price per share
$1.03
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
30,693,293
Total reported value
$30,691,617
% of total 13F portfolios
0%
Share change
-3,847,451
Value change
-$7,374,797
Number of holders
59
Price from insider filings
$1.03
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • TCRX - TScan Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share is tracked under CUSIP 89854M101.
  • 59 institutions reported positions in Q4 2025.
  • 7 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 59 to 0 between Q4 2025 and Q1 2026.
  • Reported value moved from $30,691,617 to $0.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 59 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 89854M101?
CUSIP 89854M101 identifies TCRX - TScan Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of TScan Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share (TCRX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Lynx1 Capital Management LP 15% +37% $11,393,153 +$3,625,000 7,857,347 +47% Lynx1 Capital Management LP 30 Jun 2025
BIOTECHNOLOGY VALUE FUND L P 10% $8,421,666 5,263,541 BVF PARTNERS L P/IL 31 Mar 2025
K2 HealthVentures Equity Trust LLC 6.9% $5,764,320 3,602,700 K2 HealthVentures Equity Trust LLC 31 Dec 2024
ADAGE CAPITAL PARTNERS GP, L.L.C. 7.1% $5,600,000 3,500,000 Adage Capital Management, L.P. 31 Dec 2024
Adage Capital Management, L.P. 2.5% $1,957,500 1,350,000 Adage Capital Management, L.P. 30 Jun 2025
BlackRock, Inc. 1.8% -72% $1,475,894 -$2,875,873 958,373 -66% BlackRock, Inc. 30 Jun 2025
EcoR1 Capital, LLC 1.3% $1,060,533 662,833 EcoR1 Capital, LLC 31 Mar 2025

As of 31 Dec 2025, 59 institutional investors reported holding 30,693,293 shares of TScan Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share (TCRX). This represents 59% of the company’s total 52,382,313 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of TScan Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share (TCRX) together control 57% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Lynx1 Capital Management LP 15% 8,019,148 +2.1% 1.6% $8,019,148
BVF INC/IL 10% 5,226,074 0% 0.18% $5,226,074
BAKER BROS. ADVISORS LP 5.3% 2,784,792 0% 0.02% $2,784,792
VANGUARD GROUP INC 4.7% 2,475,733 +6.8% 0% $2,475,733
BlackRock, Inc. 3.5% 1,848,695 -22% 0% $1,848,695
Aberdeen Group plc 3.4% 1,785,241 +32% 0% $1,785,241
Deer Management Co. LLC 2.4% 1,245,504 0% 0.12% $1,245,504
RENAISSANCE TECHNOLOGIES LLC 2.2% 1,141,069 +37% 0% $1,141,069
TWO SIGMA INVESTMENTS, LP 1.2% 651,179 +55% 0% $651,179
DC Funds, LP 1.2% 630,000 0% 43% $630,000
GEODE CAPITAL MANAGEMENT, LLC 1.1% 562,153 -0.97% 0% $562,360
MILLENNIUM MANAGEMENT LLC 0.77% 403,618 -13% 0% $403,618
JANE STREET GROUP, LLC 0.74% 388,284 +378% 0% $388,284
TWO SIGMA ADVISERS, LP 0.68% 353,900 +23% 0% $353,900
MARSHALL WACE, LLP 0.65% 339,240 +628% 0% $339,240
GSA CAPITAL PARTNERS LLP 0.43% 226,164 0.02% $226,000
MORGAN STANLEY 0.43% 225,829 -73% 0% $225,829
XTX Topco Ltd 0.42% 219,001 +1142% 0.01% $219,001
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.41% 216,133 +171% 0% $216,133
STATE STREET CORP 0.4% 207,313 +5.1% 0% $207,313
JACOBS LEVY EQUITY MANAGEMENT, INC 0.36% 188,152 0% $188,152
CITADEL ADVISORS LLC 0.31% 162,877 -58% 0% $162,877
BROWN BROTHERS HARRIMAN & CO 0.27% 143,051 0% 0% $143,051
BRIDGEWAY CAPITAL MANAGEMENT, LLC 0.22% 115,400 -18% 0% $115,400
NORTHERN TRUST CORP 0.19% 98,198 -0.36% 0% $98,198

Institutional Holders of TScan Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share (TCRX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 0 $0 -$10,000 $1.03 0
2025 Q4 30,693,293 $30,691,617 -$7,374,797 $1.00 59
2025 Q3 34,601,160 $62,910,264 -$1,894,623 $1.82 72
2025 Q2 35,724,879 $51,820,655 -$5,881,550 $1.45 79
2025 Q1 40,135,840 $55,389,702 -$2,855,488 $1.38 92
2024 Q4 41,522,755 $126,231,784 -$5,917,073 $3.04 87
2024 Q3 41,835,445 $208,343,506 +$256,552 $4.98 86
2024 Q2 41,438,662 $242,461,718 +$40,505,361 $5.85 78
2024 Q1 34,291,369 $272,339,183 +$19,079,789 $7.94 65
2023 Q4 31,912,819 $186,051,742 +$7,213,515 $5.83 54
2023 Q3 28,588,231 $73,196,468 +$2,177,876 $2.56 32
2023 Q2 27,951,619 $69,879,871 +$45,817,232 $2.50 28
2023 Q1 9,667,555 $20,309,551 +$609,616 $2.10 28
2022 Q4 9,519,305 $14,788,379 -$121,391 $1.55 28
2022 Q3 9,508,092 $29,003,732 -$530,741 $3.05 24
2022 Q2 9,682,082 $30,449,817 +$1,528,632 $3.14 23
2022 Q1 9,407,022 $26,340,000 -$1,500,189 $2.80 24
2021 Q4 9,861,945 $44,380,000 -$2,457,435 $4.50 28
2021 Q3 9,504,939 $78,230,000 +$78,229,998 $8.34 25